Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2022-06-09 Director's Dealing
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2022-06-09 English
PRIMARY DOCUMENT
Director's Dealing
2022-06-03 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2022, by Apellis Pharmaceuticals, Inc. The key content is under Item 5.07, which details the submission of matters to a vote of security holders at the Annual Meeting of Stockholders held on June 1, 2022. It includes voting results for director elections, ratification of the independent auditor, and advisory vote on executive compensation. The document is short (3925 characters) and focuses solely on reporting the official results of shareholder votes at the annual meeting. There is no detailed financial data or management discussion, nor is it a full annual report or earnings release. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)". Therefore, the correct classification is DVA with high confidence.
2022-06-02 English
PRIMARY DOCUMENT
Director's Dealing
2022-05-31 English
PRIMARY DOCUMENT
Director's Dealing
2022-05-17 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.